In Table 1, all patient and tumor characteristics of the entire cohort, concurrent/sequential PD-1 inhibition (nivolumab subgroup) and sequential PD-L1 inhibition (durvalumab subgroup) are shown. Here, PDCD1 is linked to neoplasm.